The Psychedelic Fund That Grew Into a Bet on the Whole Brain

PsyMed Ventures started with a podcast and a narrow question about psychedelic medicine. Six years later, its portfolio makes a broader wager: that the next important health companies will treat the brain as biology, data and lived experience at once.